Prostate Cancer: Molecular Imaging and Radionuclide Therapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2576
Special Issue Editor
Special Issue Information
Dear Colleagues,
I am thrilled to announce the upcoming release of a Special Issue in Biomedicines, entitled "Prostate Cancer: Molecular Imaging and Radionuclide Therapy." This collection of articles will feature contributions from leading experts in the field of positron emission tomography/computed tomography (PET/CT) and radionuclide therapies for prostate cancer. The rapidly evolving field of theranostics, which combines diagnostic and therapeutic radiopharmaceutical agents, is revolutionizing prostate cancer imaging and paving the way for improved treatment strategies. This Special Issue aims to highlight recent advancements in molecular imaging and radionuclide therapy that have already impacted the management of prostate cancer and those that have the potential to shape the diagnostic and treatment paths of the disease in the near future.
Dr. Sara Harsini
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- theranostics
- positron emission tomography
- PET
- radionuclide therapy
- prostate-specific membrane antigen